NuGenerex Immuno-Oncology Announces Plans to Address the New Emerging Pandemic Threat from G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine

Nachrichtenquelle: globenewswire
02.07.2020, 15:00  |  232   |   |   
  • NGIO has previously developed Ii-Key-H1 peptides for vaccines against epitopes to 2009 Swine Flu and 2004 Bird Flu with positive Phase I clinical safety and immunologic data for Ii-Key-H1 peptide vaccine
  • Ii-Key-H1 peptide sequence is 100% homologous in previous pandemic influenza threats
  • Potential to launch Ii-Key-H1 peptide vaccine for emerging pandemic threat from G4 EA H1N1 swine flu
  • Published reference: Honglei et al. Prevalent Eurasian Avian-like H1N1 Swine Influenza Virus with 2009 Pandemic Viral Genes Facilitating Human Infection. Proceedings of the National Academy of Sciences; June 2020. (See Link) ...

MIRAMAR, Fla., July 02, 2020 (GLOBE NEWSWIRE) -- NuGenerex Immuno-Oncology today announced that the company is launching a vaccine development effort to address the new, emerging pandemic threat from a newly identified swine influenza virus. On June 29, 2020 scientists in China published a paper in the Proceedings of the National Academy of Sciences identifying a new virus in pigs that has the capacity to infect humans. This emerging virus is similar to the 2009 swine flu virus that is estimated to have killed nearly 500,000 globally. Between April 12, 2009, and April 10, 2010, the CDC estimates that the 2009 swine flu virus caused 60.8 million illnesses, 273,304 hospitalizations and 12,469 deaths in the United States. Of particular concern is that an infection surveillance program with swine workers showed an elevated level of antibodies to the G4 EA H1 influenza virus, indicating swine to human transmission and the potential for another viral pandemic. NGIO is uniquely positioned to respond this pandemic threat as the company has successfully completed a Phase I human clinical trial with an Ii-Key peptide vaccine designed to elicit an immune response against the H1 hemagglutinin protein of the 2009 H1 swine influenza strain.

Joseph Moscato, CEO of NGIO stated, “Our Ii-Key immune activation technology is designed to create targeted, highly specific vaccines that activate both the T-Cell and antibody responses that make a “Complete Vaccine” against cancer antigens and viruses. The Ii-Key technology platform was established to respond quickly, economically, and effectively to create vaccines against viral and cancer antigens based upon the amino acid peptide sequences of the target proteins that can be neutralized by an immune response. Importantly, Ii-Key peptide vaccines have demonstrated safety, without signs of off-target immune responses or cytokine storm effects in any of the Phase I and Phase II trials conducted to date. As such, the Ii-Key platform is perfectly suited for inclusion in a pandemic preparedness portfolio, and we plan to pursue this avenue to augment our clinical development program for Ii-Key immunotherapeutic cancer vaccines as we progress toward a public listing for NuGenerex Immuno-Oncology on a national exchange.”

Seite 1 von 3
Generex Biotechnology Aktie jetzt ab 0€ handeln - auf

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



Meistgelesene Nachrichten des Autors


Diskussionen zu den Werten

19:37 Uhr